AFX-2101

AFX-2101 is a small molecule therapeutic candidate currently in preclinical development by Afecta Pharmaceuticals. It is being investigated for the treatment of central nervous system (CNS) trauma, a category that typically encompasses traumatic brain injury (TBI) and spinal cord injury. While the specific molecular target and mechanism of action have not been publicly disclosed, the program is part of Afecta's pipeline focused on neuroprotection and neuroregeneration. The company often utilizes proprietary drug delivery and formulation technologies to optimize the therapeutic profile of its assets, aiming to address significant unmet needs in acute and chronic neurological damage.